ENTRY       D05218                      Drug
NAME        Ocrelizumab (USAN);
            Ocrelizumab (genetical recombination) (JAN);
            Ocrevus (TN)
PRODUCT     OCREVUS (Genentech)
FORMULA     C6494H9978N1718O2014S46
EXACT_MASS  145725.8326
MOL_WEIGHT  145816.0033
REMARK      ATC code: L04AA36
            Product: D05218<US>
EFFICACY    Antirheumatic, Anti-CD20 antibody
  DISEASE   Multiple sclerosis [DS:H01490]
  TYPE      Monoclonal antibody
COMMENT     Treatment of rheumatoid arthritis
TARGET      CD20 [HSA:931] [KO:K06466]
  PATHWAY   hsa04640(931)  Hematopoietic cell lineage
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AA Selective immunosuppressants
                 L04AA36 Ocrelizumab
                  D05218  Ocrelizumab (USAN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Central Nervous System Agents
              Multiple Sclerosis Agents
               Ocrelizumab
                D05218  Ocrelizumab (USAN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD20
                 D05218  Ocrelizumab (USAN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D05218
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D05218
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D05218
DBLINKS     CAS: 637334-45-3
            PubChem: 47206937
///
